Progress of Diagnosis and Treatment in Male Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 ZHAOBao-guo ,  DAIWen-jie

Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin 150001, Heilongjiang Province, China;

Corresponding author：

DAIWen-jie, Email: davidhmu@163.com

Keywords：

Male breast cancer; Diagnosis; Treatment; Risk factor; Molecular subtypes

DOI：

10.7507/1007-9424.20150197

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the progress of diagnosis and treatment in male breast cancer. Methods The literatures about the research progress of diagnosis and treatment in male breast cancer were reviewed. Results The diagnosis of male breast cancer relied mainly on clinical manifestations and imaging manifestations, the main treatment of male breast cancer was modified radical operation, combining with radiotherapy, chemotherapy, endocrine therapy, and targeted therapy. Conclusions The treatment of male breast cancer is mainly reference the treatment of female breast cancer, which is lack of a clear standard of treatment. Indepth study on the molecular genetic level will provide more accurate care decisions for the treatment of male breast cancer.

Citation： ZHAOBao-guo, DAIWen-jie. Progress of Diagnosis and Treatment in Male Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(6): 759-762. doi: 10.7507/1007-9424.20150197 Copy

1.	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1):11-30.
2.	Zygogianni AG, Kyrgias G, Gennatas C, et al. Male breast carcinoma:epidemiology, risk factors and current therapeutic approaches. Asian Pac J Cancer Prev, 2012, 13(1):15-19.
3.	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56(2):106-130.
4.	Salehi A, Zeraati H, Mohammad K, et al. Survival of male breast cancer in fars, south of Iran. Iran Red Crescent Med J, 2011, 13(2):99-105.
5.	Baojiang L, Tingting L, Gang L, et al. Male breast cancer:a retrospective study comparing survival with female breast cancer. Oncol Lett, 2012, 4(4):642-646.
6.	Shah S, Bhattacharyya S, Gupta A, et al. Male breast cancer:a clinicopathologic study of 42 patients in eastern India. Indian J Surg Oncol, 2012, 3(3):245-249.
7.	Patten DK, Sharifi LK, Fazel M. New approaches in the management of male breast cancer. Clin Breast Cancer, 2013, 13(5):309-314.
8.	Ewertz M, Holmberg L, Tretli S, et al. Risk factors for male breast cancer-a case-control study from Scandinavia. Acta Oncol, 2001, 40(4):467-471.
9.	Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res, 2002, 4(1):R2.
10.	Orr N, Lemnrau A, Cooke R, et al. Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet, 2012, 44(11):1182-1184.
11.	Thellenberg C, Malmer B, Tavelin B, et al. Second primary cancers in men with prostate cancer:an increased risk of male breast cancer. J Urol, 2003, 169(4):1345-1348.
12.	Ron E, Ikeda T, Preston DL, et al. Male breast cancer incidence among atomic bomb survivors. J Natl Cancer Inst, 2005, 97(8):603-605.
13.	薛妍, 郭晓彤, 刘文超.男性乳腺癌的临床研究进展.癌症, 2007, 26(10):1148-1152.
14.	Coyle YM, Hynan LS, Euhus DM, et al. An ecological study of the association of environmental chemicals on breast cancer incidence in Texas. Breast Cancer Res Treat, 2005, 92(2):107-114.
15.	Ruddy KJ, Winer EP. Male breast cancer:risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol, 2013, 24(6):1434-1443.
16.	Morrogh M, King TA. The significance of nipple discharge of the male breast. Breast J, 2009, 15(6):632-638.
17.	吴雅媛, 王彤, 刘红.男性乳腺癌125例患者的临床病理特征与生存分析.肿瘤, 2012, 32(10):805-810.
18.	Fentiman IS, Fourquet A, Hortobaqyi GN. Male breast cancer. Lancet, 2006, 367(9510):595-604.
19.	Ottini L, Silvestri V, Rizzolo P, et al. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients:results from a collaborative multicenter study in Italy. Breast Cancer Res Treat, 2012, 134(1):411-418.
20.	余小琴, 高军喜, 姚兰辉, 等.乳腺癌超声征象与淋巴结转移关系的单因素及多因素分析.中华超声影像学杂志, 2010, 19(4):317-320.
21.	吴艳艳, 彭玉兰.超声弹性成像定性诊断乳腺癌.中国医学影像技术, 2014, 30(5):738-741.
22.	李俊来, 鲁媛媛, 王国昌, 等.提高乳腺钙化灶超声显示率的临床研究.中华超声影像学杂志, 2011, 20(3):234-236.
23.	Nilsson C, Koliadi A, Johansson I, et al. High proliferation is associated with inferior outcome in male breast cancer patients. Mod Pathol, 2013, 26(1):87-94.
24.	Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol, 2009, 27(34):5700-5706.
25.	Nilsson C, Johansson I, Ahlin C, et al. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol, 2013, 52(1):102-109.
26.	刘新丽, 刘芳芳, 郑屹, 等.男性乳腺癌临床病理特征及预后分析.中国肿瘤临床, 2014, 41(23):1521-1526.
27.	Goss PE, Reid C, Pintilie M, et al. Male breast carcinoma:a review of 229 patients who presented to the Princess Margaret Hospital during 40 years:1955-1966. Cancer, 1999, 85(3):629-639.
28.	Boughey JC, Bedrosian I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg, 2006, 203(4):475-480.
29.	Garcia SF, Rosenbloom SK, Beaumont JL, et al. Priority symptoms in advanced breast cancer:development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16). Value Health, 2012, 15(1):183-190.
30.	艾秀清, 任云凤, 朱相露, 等.男性乳腺癌患者术后放射治疗疗效观察.中国实用医药, 2014, 9(20):38-39.
31.	张青松, 霍彦平, 李明闯, 等.放疗对乳腺癌改良根治术后不同基因型患者预后的影响.中国现代医学杂志, 2014, 24(32):67-72.
32.	Bratman SV, Kapp DS, Horst KC. Evolving trends in the initial locoregional management of male breast cancer. Breast, 2012, 21(3):296-302.
33.	Nwashilli NJ, Ugiagbe EE. Bilateral synchronous male breast cancer. Saudi Med J, 2015, 36(3):359-362.
34.	Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol, 2013, 717(1-3):71-83.
35.	Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol, 2010, 73(3):246-254.
36.	Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer, 2005, 104(11):2359-2364.
37.	Tarone RE, Chu KC. The greater impact of menopause on ER^- than ER⁺ breast cancer incidence:a possible explanation (United States). Cancer Causes Control, 2002, 13(1):7-14.
38.	Chen X, Liu X, Zhang L, et al. Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences. Jpn J Clin Oncol, 2013, 43(10):954-963.
39.	Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial.Lancet, 2013, 381(9869):805-816.
40.	Pemmaraju N, Munsell MF, Hortobagyi GN, et al.Retrospective review of male breast cancer patients:analysis of tamoxifen-related side-effects.Ann Oncol, 2012, 23(6):1471-1474.
41.	卢晓婷, 张亚芬, 高润芳.男性乳腺癌内分泌治疗17例临床观察.实用医技杂志, 2015, 22(1):67-68.
42.	42高国璇, 刘荫华.2014年ASCO乳腺癌临床实践指南解读——HER2阴性(或未知)晚期乳腺癌化学和靶向治疗.中国实用外科杂志, 2015, 35(1):27-29.
43.	Arslan UY, Oksüzoğlu B, Ozdemir N, et al.Outcome of nonmetastatic male breast cancer:118 patients.Med Oncol, 2012, 29(2):554-560.
44.	44王丽娜, 严颖, 李惠平, 等.男性乳腺癌25例的临床病理特征及生存分析.癌症进展, 2014, 12(1):64-69.
45.	45高国璇, 辛灵, 刘倩, 等.St Gallen国际乳腺癌会议专家共识10年历程回顾.中国实用外科杂志, 2014, 34(1):70-72.

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1):11-30.
2. Zygogianni AG, Kyrgias G, Gennatas C, et al. Male breast carcinoma:epidemiology, risk factors and current therapeutic approaches. Asian Pac J Cancer Prev, 2012, 13(1):15-19.
3. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56(2):106-130.
4. Salehi A, Zeraati H, Mohammad K, et al. Survival of male breast cancer in fars, south of Iran. Iran Red Crescent Med J, 2011, 13(2):99-105.
5. Baojiang L, Tingting L, Gang L, et al. Male breast cancer:a retrospective study comparing survival with female breast cancer. Oncol Lett, 2012, 4(4):642-646.
6. Shah S, Bhattacharyya S, Gupta A, et al. Male breast cancer:a clinicopathologic study of 42 patients in eastern India. Indian J Surg Oncol, 2012, 3(3):245-249.
7. Patten DK, Sharifi LK, Fazel M. New approaches in the management of male breast cancer. Clin Breast Cancer, 2013, 13(5):309-314.
8. Ewertz M, Holmberg L, Tretli S, et al. Risk factors for male breast cancer-a case-control study from Scandinavia. Acta Oncol, 2001, 40(4):467-471.
9. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res, 2002, 4(1):R2.
10. Orr N, Lemnrau A, Cooke R, et al. Genome-wide association study identifies a common variant in RAD51B associated with male breast cancer risk. Nat Genet, 2012, 44(11):1182-1184.
11. Thellenberg C, Malmer B, Tavelin B, et al. Second primary cancers in men with prostate cancer:an increased risk of male breast cancer. J Urol, 2003, 169(4):1345-1348.
12. Ron E, Ikeda T, Preston DL, et al. Male breast cancer incidence among atomic bomb survivors. J Natl Cancer Inst, 2005, 97(8):603-605.
13. 薛妍, 郭晓彤, 刘文超.男性乳腺癌的临床研究进展.癌症, 2007, 26(10):1148-1152.
14. Coyle YM, Hynan LS, Euhus DM, et al. An ecological study of the association of environmental chemicals on breast cancer incidence in Texas. Breast Cancer Res Treat, 2005, 92(2):107-114.
15. Ruddy KJ, Winer EP. Male breast cancer:risk factors, biology, diagnosis, treatment, and survivorship. Ann Oncol, 2013, 24(6):1434-1443.
16. Morrogh M, King TA. The significance of nipple discharge of the male breast. Breast J, 2009, 15(6):632-638.
17. 吴雅媛, 王彤, 刘红.男性乳腺癌125例患者的临床病理特征与生存分析.肿瘤, 2012, 32(10):805-810.
18. Fentiman IS, Fourquet A, Hortobaqyi GN. Male breast cancer. Lancet, 2006, 367(9510):595-604.
19. Ottini L, Silvestri V, Rizzolo P, et al. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients:results from a collaborative multicenter study in Italy. Breast Cancer Res Treat, 2012, 134(1):411-418.
20. 余小琴, 高军喜, 姚兰辉, 等.乳腺癌超声征象与淋巴结转移关系的单因素及多因素分析.中华超声影像学杂志, 2010, 19(4):317-320.
21. 吴艳艳, 彭玉兰.超声弹性成像定性诊断乳腺癌.中国医学影像技术, 2014, 30(5):738-741.
22. 李俊来, 鲁媛媛, 王国昌, 等.提高乳腺钙化灶超声显示率的临床研究.中华超声影像学杂志, 2011, 20(3):234-236.
23. Nilsson C, Koliadi A, Johansson I, et al. High proliferation is associated with inferior outcome in male breast cancer patients. Mod Pathol, 2013, 26(1):87-94.
24. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol, 2009, 27(34):5700-5706.
25. Nilsson C, Johansson I, Ahlin C, et al. Molecular subtyping of male breast cancer using alternative definitions and its prognostic impact. Acta Oncol, 2013, 52(1):102-109.
26. 刘新丽, 刘芳芳, 郑屹, 等.男性乳腺癌临床病理特征及预后分析.中国肿瘤临床, 2014, 41(23):1521-1526.
27. Goss PE, Reid C, Pintilie M, et al. Male breast carcinoma:a review of 229 patients who presented to the Princess Margaret Hospital during 40 years:1955-1966. Cancer, 1999, 85(3):629-639.
28. Boughey JC, Bedrosian I, Meric-Bernstam F, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg, 2006, 203(4):475-480.
29. Garcia SF, Rosenbloom SK, Beaumont JL, et al. Priority symptoms in advanced breast cancer:development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16). Value Health, 2012, 15(1):183-190.
30. 艾秀清, 任云凤, 朱相露, 等.男性乳腺癌患者术后放射治疗疗效观察.中国实用医药, 2014, 9(20):38-39.
31. 张青松, 霍彦平, 李明闯, 等.放疗对乳腺癌改良根治术后不同基因型患者预后的影响.中国现代医学杂志, 2014, 24(32):67-72.
32. Bratman SV, Kapp DS, Horst KC. Evolving trends in the initial locoregional management of male breast cancer. Breast, 2012, 21(3):296-302.
33. Nwashilli NJ, Ugiagbe EE. Bilateral synchronous male breast cancer. Saudi Med J, 2015, 36(3):359-362.
34. Sousa B, Moser E, Cardoso F. An update on male breast cancer and future directions for research and treatment. Eur J Pharmacol, 2013, 717(1-3):71-83.
35. Cutuli B, Le-Nir CC, Serin D, et al. Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol, 2010, 73(3):246-254.
36. Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer, 2005, 104(11):2359-2364.
37. Tarone RE, Chu KC. The greater impact of menopause on ER^- than ER⁺ breast cancer incidence:a possible explanation (United States). Cancer Causes Control, 2002, 13(1):7-14.
38. Chen X, Liu X, Zhang L, et al. Poorer survival of male breast cancer compared with female breast cancer patients may be due to biological differences. Jpn J Clin Oncol, 2013, 43(10):954-963.
39. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS, a randomised trial.Lancet, 2013, 381(9869):805-816.
40. Pemmaraju N, Munsell MF, Hortobagyi GN, et al.Retrospective review of male breast cancer patients:analysis of tamoxifen-related side-effects.Ann Oncol, 2012, 23(6):1471-1474.
41. 卢晓婷, 张亚芬, 高润芳.男性乳腺癌内分泌治疗17例临床观察.实用医技杂志, 2015, 22(1):67-68.
42. 42高国璇, 刘荫华.2014年ASCO乳腺癌临床实践指南解读——HER2阴性(或未知)晚期乳腺癌化学和靶向治疗.中国实用外科杂志, 2015, 35(1):27-29.
43. Arslan UY, Oksüzoğlu B, Ozdemir N, et al.Outcome of nonmetastatic male breast cancer:118 patients.Med Oncol, 2012, 29(2):554-560.
44. 44王丽娜, 严颖, 李惠平, 等.男性乳腺癌25例的临床病理特征及生存分析.癌症进展, 2014, 12(1):64-69.
45. 45高国璇, 辛灵, 刘倩, 等.St Gallen国际乳腺癌会议专家共识10年历程回顾.中国实用外科杂志, 2014, 34(1):70-72.

Previous Article
Clinical Research Progress of HER-2/neu Gene in Gastric Cancer
Next Article
Research Progress of Mucinous Breast Cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Progress of Diagnosis and Treatment in Male Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content